PGGM Investments decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 7.7% during the fourth quarter, Holdings Channel.com reports. The firm owned 1,910,729 shares of the biopharmaceutical company’s stock after selling 160,362 shares during the period. PGGM Investments’ holdings in Gilead Sciences were worth $124,159,000 at the end of the most recent reporting period.
Other institutional investors have also added to or reduced their stakes in the company. First Financial Corp IN grew its holdings in shares of Gilead Sciences by 286.4% in the third quarter. First Financial Corp IN now owns 541 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 401 shares during the last quarter. M&R Capital Management Inc. grew its holdings in shares of Gilead Sciences by 83.3% in the fourth quarter. M&R Capital Management Inc. now owns 550 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 250 shares during the last quarter. Venturi Wealth Management LLC bought a new position in shares of Gilead Sciences in the third quarter worth about $40,000. Front Row Advisors LLC grew its holdings in shares of Gilead Sciences by 286.0% in the second quarter. Front Row Advisors LLC now owns 691 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 512 shares during the last quarter. Finally, Larson Financial Group LLC grew its holdings in shares of Gilead Sciences by 30.7% in the third quarter. Larson Financial Group LLC now owns 826 shares of the biopharmaceutical company’s stock worth $52,000 after purchasing an additional 194 shares during the last quarter. 79.28% of the stock is currently owned by institutional investors.
A number of research analysts have recently commented on the stock. Maxim Group cut shares of Gilead Sciences from a “buy” rating to a “hold” rating in a report on Friday, October 25th. Cantor Fitzgerald cut their price target on shares of Gilead Sciences from $88.00 to $85.00 and set an “overweight” rating on the stock in a report on Friday, October 25th. Cowen restated a “buy” rating and issued a $85.00 price target on shares of Gilead Sciences in a report on Thursday, January 2nd. Guggenheim set a $86.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Friday, October 25th. Finally, Robert W. Baird set a $76.00 price target on shares of Gilead Sciences and gave the stock a “hold” rating in a report on Friday, October 25th. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Hold” and an average target price of $78.91.
NASDAQ:GILD traded down $0.50 during mid-day trading on Friday, reaching $62.70. The company’s stock had a trading volume of 407,858 shares, compared to its average volume of 6,689,442. Gilead Sciences, Inc. has a 1 year low of $60.89 and a 1 year high of $70.50. The stock has a fifty day moving average of $65.96 and a 200-day moving average of $65.23. The firm has a market capitalization of $79.65 billion, a PE ratio of 10.20, a price-to-earnings-growth ratio of 3.90 and a beta of 1.11. The company has a quick ratio of 2.87, a current ratio of 2.96 and a debt-to-equity ratio of 1.11.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, October 24th. The biopharmaceutical company reported $1.75 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.74 by $0.01. Gilead Sciences had a net margin of 12.04% and a return on equity of 37.50%. The company had revenue of $5.60 billion during the quarter, compared to analyst estimates of $5.61 billion. During the same period in the prior year, the firm earned $1.84 earnings per share. The firm’s revenue for the quarter was up .1% compared to the same quarter last year. On average, analysts expect that Gilead Sciences, Inc. will post 6.63 earnings per share for the current year.
The company also recently declared a quarterly dividend, which was paid on Monday, December 30th. Shareholders of record on Friday, December 13th were given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 4.02%. The ex-dividend date was Thursday, December 12th. Gilead Sciences’s payout ratio is 40.98%.
Gilead Sciences Profile
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Featured Article: Commodities
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.